A Safety and Efficacy Study of Two Dosage Levels of Pulmicort Respules (budesonideinhalation suspension, 0.5 or 1.0 mg/day) versus Placebo in Infants Between the Ages of Six and TwelveMonths with Mild to Moderate Asthma.

Study identifier:SD-004-0732

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Safety and Efficacy Study of Two Dosage Levels of Pulmicort Respules (budesonideinhalation suspension, 0.5 or 1.0 mg/day) versus Placebo in Infants Between the Ages of Six and TwelveMonths with Mild to Moderate Asthma.

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Sept 2000

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2096&filename=CSR-SD-004-0732.pdf
Download
CSR-SD-004-0732.pdf
Download
Trial Results Summaries
Available here

A Safety and Efficacy Study of Two Dosage Levels of Pulmicort Respules (budesonideinhalation suspension, 0.5 or 1.0 mg/day) versus Placebo in Infants Between the Ages of Six and TwelveMonths with Mild to Moderate Asthma.

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2096&filename=CSR-SD-004-0732.pdf

CSR-SD-004-0732.pdf

Trial Results Summaries